



***CLIENT UPDATE ***
Change in Methodology for
Factor V Leiden, Factor II (Prothrombin)
and MTHFR Mutation Detection

776 Melrose Avenue, Nashville TN 37211 . phone 615.687.7900 . fax 615.687.7920 . www.pathgroup.com

PATHGROUP LABS METHODOLOGY CHANGE

Effective October 19, 2005

PathGroup Labs is offering a new technology for the detection of Factor V Leiden, Factor II G20210A (Prothrombin), MTHFR A1298C, and MTHFR C677T mutations, the four most common mutations associated with an increased risk of hereditary thrombophilia and hyperhomocystinemia related to coronary artery disease as well as other thrombotic disorders.

The new methodology, TM Biosciences Tag-It™ Mutation Detection assay, has been formatted to accurately genotype either one, two or all four of these mutations simultaneously by incorporating multiplex PCR and multiplex Allele Specific Primer Extension (ASPE) with the Universal Tag sorting system on the Luminex® 100 xMAP™ platform. It is recommended that the DNA sample be extracted from whole blood.

This technology meets our high standards and enables PathGroup Labs to address the growing demand for genetic screening. We are working hard to provide the highest quality clinical laboratory services, which consistently exceed the expectations of our clients, physicians, employees, payers, and most importantly, our patients.

If you have any questions concerning this memo, please feel free to call our Client Services Department at 615-234-0781 or 1-888-474-5227 or the clinical laboratory at 615-687-7900.

Samuel Smith MD,
Medical Director
PathGroup Labs

Safedin H. Beqaj PhD,
Technical Director
PathGroup Labs